Hospital Injectable Products · LP-202
Sodium chloride Injection
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-202Hospital Injectable Products
- Generic identity
- Sodium chlorideInjection
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-202
- Generic ingredient
- Sodium chloride
- Dosage form
- Injection
- Proposed strength
- 0.9% 10 mL ampoule; 0.9% 500 mL IV infusion
- Proposed pack
- Ampoule or IV bottle/bag
- Portfolio category
- Hospital Injectable Products
About Sodium chloride
Sodium chloride injection supplies sodium and chloride in a sterile fluid. The source record includes small ampoules and larger intravenous infusion containers at the same stated concentration. Although the ingredient is shared, container purpose and authorized use may differ. An ampoule is not automatically a flush, diluent, irrigation product or direct infusion simply because it contains saline.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Clinical decisions distinguish fluid replacement from a specifically authorized role in medicine preparation or line care. Fluid choice depends on the underlying problem, circulatory status, electrolytes and other treatment. Large-volume saline administration can affect acid-base balance and does not provide all nutrients or electrolytes needed in every situation. The catalogue’s volumes are presentation details and do not establish a fluid-management protocol or approved device compatibility.
Important safety considerations
Excessive administration can cause fluid overload, oedema and electrolyte disturbances. Chloride load can contribute to an acid-base disturbance in relevant settings. Heart or kidney disease and altered sodium balance require particular assessment. Nonsterile handling or use of an inappropriate container can introduce infection or compatibility risks. Confirm that a product is authorized for its intended route and use; injection and irrigation products must not be casually interchanged.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The 10 mL ampoule and 500 mL infusion require separate container and intended-use specifications. Confirm sterility designation, preservative content, single-use status, port compatibility and any authorized dilution or flushing role in the actual label.
Professional preparation must follow the authorized label and local aseptic procedures. Confirm the correct container, concentration, route and expiry before use. Storage, transport, dilution compatibility and any period after opening or reconstitution require product-specific evidence; this page does not establish them.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Confirm the fluid or preparation purpose, circulatory and electrolyte status, appropriate container and compatibility. Match the exact saline product to the clinical protocol.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Sodium chloride
- Dosage form / presentation
- Injection
- Catalogue strength
- 0.9% 10 mL ampoule; 0.9% 500 mL IV infusion
- Catalogue pack
- Ampoule or IV bottle/bag
- Portfolio category
- Hospital Injectable Products
Layer 02
Unresolved product-specific fields
- P019 — The strength field already pairs 0.9% with two distinct presentations: 10 mL ampoule and 500 mL IV infusion. Those pairings must remain intact and must not be cross-multiplied into hypothetical container/SKU combinations.
- The catalogue explicitly identifies the 500 mL presentation as an IV infusion; it does not establish that the 10 mL ampoule has the same intended use, container function or route.
- Approved indication, patient eligibility and dosing or test interpretation are not established by this portfolio record.
- Registration/authorization, manufacturing or site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- DailyMed: sodium chloride injection, solution — external comparatorgovernment-hosted external product label
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Variant matrix preserving the exact 0.9%/10 mL ampoule and 0.9%/500 mL IV-infusion pairings, with container function, route, composition, sterility and handling controls confirmed separately.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-202, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-202.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.